Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of its Lidocaine Patch 5%, which is the generic version of Endo Pharmaceutical's Lidoderm®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for relief of pain associated with post-herpetic neuralgia.
URL:
www.prnewswire.com/news-releases/mylan-launches-generic-version-of-lidoderm-patch-300125881.html
URL:
www.prnewswire.com/news-releases/mylan-launches-generic-version-of-lidoderm-patch-300125881.html
No comments:
Post a Comment